Affordable Access

deepdyve-link
Publisher Website

[Cytokines in bone diseases. Anti-cytokine therapies for bone and joint diseases].

Authors
  • Tanaka, Yoshiya
Type
Published Article
Journal
Clinical calcium
Publication Date
Oct 01, 2010
Volume
20
Issue
10
Pages
1545–1552
Identifiers
DOI: CliCa101015451552
PMID: 20890038
Source
Medline
License
Unknown

Abstract

The efficacy of biologics targeting inflammatory cytokines such as TNF and IL-6 for bone and joint diseases has been emerging. Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic synovitis and bone damage. By the use of TNF-inhibitors, clinical remission, structural remission and functional remission have become possible during the treatment of RA. Especially, the progress of joint and bone destruction is completely suppressed by TNF-inhibitors in the vast majority of RA patients. On the other hand, anti-RANKL antibody inhibits joint destruction as well as systemic osteoporosis, though no effects on synovitis of RA. Thus, differential efficacy of different therapies in bone destruction and osteoporosis would warrant further study to clarify the mechanisms of bone and joints diseases.

Report this publication

Statistics

Seen <100 times